AbTCR-CSR therapeutic trial in an AML animal model. (A) Human AML cell line AML-14 cells (5 million) were injected IV into NSG mice and leukemia engraftment was confirmed on day 13 by bioluminescent imaging. (B) AbTCR-CSR clone no. 18, AbTCR-CSR clone no. 34, or control mock T cells (6 million cell per mouse) were injected IV, and tumor burden was monitored by BLI on days 18 and 21. (C) Mean tumor burden was calculated by summing the luminescence signal of each mouse and presenting the average signal for each group (n = 5 per group). (D) Survival of mice from experimental groups; a comparison of the differences of clone no. 18 or no. 34 vs the 2 control groups was performed using the Mantel-Cox test; ∗∗∗∗P < .0001.